ANI Pharmaceuticals (ANIP) Set to Announce Earnings on Thursday

Posted by Stanley Muller on Nov 4th, 2026

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) is expected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect ANI Pharmaceuticals to post earnings of $2.18 per share and revenue of $280.26 million for the quarter. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Investors may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last posted its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The firm had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company’s revenue was up 25.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.80 EPS. On average, analysts expect ANI Pharmaceuticals to post $7.76 EPS for the current fiscal year and $8.32 EPS for the next fiscal year.

ANI Pharmaceuticals Trading Up 2.3%

Shares of ANIP stock opened at $72.28 on Wednesday. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals has a fifty-two week low of $69.58 and a fifty-two week high of $95.57. The firm’s 50 day moving average price is $72.82 and its two-hundred day moving average price is $77.55. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of 15.58, a price-to-earnings-growth ratio of 2.28 and a beta of 0.45.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 500 shares of the stock in a transaction that occurred on Tuesday, October 13th. The shares were sold at an average price of $73.59, for a total value of $36,795.00. Following the completion of the sale, the vice president owned 73,424 shares of the company’s stock, valued at $5,403,272.16. This trade represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeanne Thoma sold 1,000 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $71.53, for a total transaction of $71,530.00. Following the completion of the sale, the director directly owned 26,762 shares of the company’s stock, valued at $1,914,285.86. This trade represents a 3.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 30,412 shares of company stock worth $2,220,970 over the last 90 days. 8.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ANIP has been the topic of a number of research reports. Oppenheimer assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 target price on the stock. Canaccord Genuity Group decreased their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Guggenheim lowered their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday, August 10th. Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 price target for the company. Finally, Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Hold” and an average target price of $99.60.

Check Out Our Latest Report on ANI Pharmaceuticals

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.